Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy
复制标题
DOI：
10.1111/j.1349-7006.2007.00557.x
复制
发表时间：
2007-09-01
期刊：
影响因子：
5.7
通讯作者：
Aizawa, Hisamichi
中科院分区：
文献类型：
--
作者：
Azuma, Koichi;Komohara, Yoshihiro;Aizawa, Hisamichi
切除修复交叉互补组1(ERCC1)、P53或硫氧还蛋白(TRX)的表达被报道与铂类药物的耐药性有关。作者评估了ERCC1、P53或TRX的表达是否可以预测接受铂类化疗的复发性非小细胞肺癌(NSCLC)患者的无进展和/或总生存率。采用免疫组织化学方法检测67例肺癌根治术后复发患者接受铂类药物化疗后切除的肺肿瘤标本中这三种蛋白的表达。ERCC1、P53和Trx免疫染色阳性者分别为29例、35例和24例。ERCC1阴性患者的中位无进展生存期(44vs26周，P=0.0075)和总生存期(73vs44周，P=0.0006)明显长于ERCC1阳性患者。P53表达阴性患者的中位生存期(70vs62周，P=0.0289)显著长于P53表达阳性患者(37.5vs36周，P=0.2465)。多因素分析显示，ERCC1表达阴性(危险比[HR]=1.3740，P=0.0147)是无进展生存的显著有利因素，ERCC1阴性表达(HR=1.6533，P=0.0018)和较好的生存状态(HR=1.9117，P=0.0017)是总体生存的显著有利因素。这项回顾性研究表明，ERCC1的免疫染色可能有助于预测接受以铂为基础的化疗的NSCLC患者根治性切除后复发的生存率，并为计划个性化化疗提供关键信息。
Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs. The authors evaluated whether ERCC1, p53, or TRX expression could predict progression-free and/or overall survival in relapsed non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Immunohistochemistry was used to examine the expression of these three proteins in resected lung tumor samples obtained from 67 patients treated with platinum-based chemotherapy against recurrent tumors after curative resection. Immunostaining for ERCC1, p53, and TRX was positive in 29, 35, and 24 patients, respectively. Patients negative for ERCC1 had a significantly longer median progression-free (44 vs 26 weeks, P = 0.0075) and overall (73 vs 44 weeks, P = 0.0006) survival than those positive for ERCC1. Patients negative for p53 expression had a significantly longer median overall (70 vs 62 weeks, P = 0.0289), but not progression-free (37.5 vs 36 weeks, P = 0.2465), survival than those positive for p53 expression. From multivariate analysis, negative ERCC1 expression (hazard ratio [HR] = 1.3740, P = 0.0147) was a significantly favorable factor for progression-free survival, and negative ERCC1 expression (HR = 1.6533, P = 0.0018) and better performance status (HR = 1.9117, P = 0.0017) were significantly favorable factors for overall survival. This retrospective study indicates that immunostaining for ERCC1 may be useful for predicting survival in NSCLC patients receiving platinum-based chemotherapy against recurrent tumors after curative resection and can provide critical information for planning personalized chemotherapy.